Patents Assigned to Beyondspring Pharmaceuticals, Inc.
-
Patent number: 11918574Abstract: Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.Type: GrantFiled: May 24, 2021Date of Patent: March 5, 2024Assignee: BeyondSpring Pharmaceuticals, Inc.Inventor: Lan Huang
-
Patent number: 11857522Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.Type: GrantFiled: February 8, 2021Date of Patent: January 2, 2024Assignee: BeyondSpring Pharmaceuticals, Inc.Inventors: Ramon Mohanlal, Lan Huang, George Kenneth Lloyd
-
Patent number: 11786523Abstract: Disclosed herein are methods of reducing or preventing thrombocytopenia, in a clinically relevant manner, that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.Type: GrantFiled: January 23, 2019Date of Patent: October 17, 2023Assignee: BEYONDSPRING PHARMACEUTICALS, INC.Inventors: Lan Huang, Ramon Mohanlal, George Kenneth Lloyd
-
Patent number: 11633393Abstract: Disclosed herein are compounds that can bind to tubulin and activate GEF-H1. Methods of using these compounds for treating cancer are also disclosed.Type: GrantFiled: January 5, 2018Date of Patent: April 25, 2023Assignee: BeyondSpring Pharmaceuticals, Inc.Inventors: Lan Huang, Santosh Ambadas Khedkar, Michel O. Steinmetz
-
Patent number: 11400086Abstract: Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel induced neutropenia using plinabulin.Type: GrantFiled: February 1, 2018Date of Patent: August 2, 2022Assignee: BeyondSpring Pharmaceuticals, Inc.Inventors: Ramon Mohanlal, Lan Huang, George Kenneth Lloyd
-
Patent number: 11254657Abstract: Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.Type: GrantFiled: February 3, 2020Date of Patent: February 22, 2022Assignee: BeyondSpring Pharmaceuticals, Inc.Inventors: Lan Huang, Aniruddh Singh
-
Patent number: 11229642Abstract: Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.Type: GrantFiled: June 5, 2017Date of Patent: January 25, 2022Assignee: BeyondSpring Pharmaceuticals, Inc.Inventors: Lan Huang, George Kenneth Lloyd, Ramon Mohanlal
-
Patent number: 11045467Abstract: Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.Type: GrantFiled: June 1, 2020Date of Patent: June 29, 2021Assignee: BeyondSpring Pharmaceuticals, Inc.Inventor: Lan Huang
-
Patent number: 10912748Abstract: Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.Type: GrantFiled: February 6, 2017Date of Patent: February 9, 2021Assignee: BeyondSpring Pharmaceuticals, Inc.Inventors: Ramon Mohanlal, Lan Huang, George Kenneth Lloyd
-
Patent number: 10668063Abstract: Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.Type: GrantFiled: March 1, 2019Date of Patent: June 2, 2020Assignee: BeyondSpring Pharmaceuticals, Inc.Inventor: Lan Huang
-
Patent number: 10550104Abstract: Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.Type: GrantFiled: December 6, 2018Date of Patent: February 4, 2020Assignee: BeyondSpring Pharmaceuticals, Inc.Inventors: Lan Huang, Aniruddh Singh
-
Patent number: 10357491Abstract: Disclosed herein are methods of treating a brain tumor by administering Plinabulin. Some embodiments relate to treatment of glioblastoma multiforme by administering Plinabulin.Type: GrantFiled: September 5, 2018Date of Patent: July 23, 2019Assignee: BeyondSpring Pharmaceuticals, Inc.Inventor: Lan Huang
-
Patent number: 10238650Abstract: Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.Type: GrantFiled: March 2, 2016Date of Patent: March 26, 2019Assignee: BeyondSpring Pharmaceuticals, Inc.Inventor: Lan Huang
-
Patent number: 10155748Abstract: Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.Type: GrantFiled: July 11, 2016Date of Patent: December 18, 2018Assignee: BeyondSpring Pharmaceuticals, Inc.Inventors: Lan Huang, Aniruddh Singh
-
Patent number: 10076518Abstract: Disclosed herein are methods of treating a brain tumor by administering Plinabulin. Some embodiments relate to treatment of glioblastoma multiforme by administering Plinabulin.Type: GrantFiled: March 2, 2016Date of Patent: September 18, 2018Assignee: BeyondSpring Pharmaceuticals, Inc.Inventor: Lan Huang
-
Patent number: 8618292Abstract: Compounds represented by the following structure (II) are disclosed: as are methods for making such compounds. Compositions and methods for treating various disease conditions including cancer and non-cancer diseases associated with vascular proliferation are also disclosed.Type: GrantFiled: July 12, 2012Date of Patent: December 31, 2013Assignee: Beyondspring Pharmaceuticals, Inc.Inventors: Michael Palladino, George Kenneth Lloyd, Yoshio Hayashi